 SAN DIEGO, Sept. 19, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento, a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain non-opioid treatments, autoimmune disease and COVID-19, today announced impressive results from an independent study conducted under real-world field conditions by INMEGEN The Institute of National Genomics Medicine, Mexico. 